Back
39
Also listed as
CNVVY
OTC
Day Range
$3.40
$3.65
52-Week Range
$2.78
$3.95
Volume
100
50D / 200D Avg
$3.15
/
$3.23
Prev Close
$3.40
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 37.1 | 0.3 |
| P/B | 4.4 | 2.9 |
| ROE % | 11.2 | 3.7 |
| Net Margin % | 7.2 | 3.8 |
| Rev Growth 5Y % | 5.2 | 10.0 |
| D/E | 1.1 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$0.32
$0.30 – $0.33
|
3.4 B | 1 |
| FY2029 |
$0.28
$0.27 – $0.29
|
3.1 B | 1 |
| FY2028 |
$0.25
$0.24 – $0.26
|
2.9 B | 1 |
Key Takeaways
Revenue grew 5.17% annually over 5 years — modest growth
ROE of 11.15% — decent returns on equity
Generating 342.45M in free cash flow
P/E of 37.05 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.74%
Cash machine — converts 191.43% of earnings into free cash flow
Growth
Revenue Growth (5Y)
5.17%
Revenue (1Y)8.91%
Earnings (1Y)-6.09%
FCF Growth (3Y)19.90%
Quality
Return on Equity
11.15%
ROIC9.95%
Net Margin7.18%
Op. Margin16.69%
Safety
Debt / Equity
1.06
Current Ratio1.53
Interest Coverage5.81
Valuation
P/E Ratio
37.05
P/B Ratio4.36
EV/EBITDA19.63
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.91% | Revenue Growth (3Y) | 7.88% |
| Earnings Growth (1Y) | -6.09% | Earnings Growth (3Y) | 17.17% |
| Revenue Growth (5Y) | 5.17% | Earnings Growth (5Y) | 11.06% |
| Profitability | |||
| Revenue (TTM) | 2.49B | Net Income (TTM) | 178.89M |
| ROE | 11.15% | ROA | 4.72% |
| Gross Margin | 55.19% | Operating Margin | 16.69% |
| Net Margin | 7.18% | Free Cash Flow (TTM) | 342.45M |
| ROIC | 9.95% | FCF Growth (3Y) | 19.90% |
| Safety | |||
| Debt / Equity | 1.06 | Current Ratio | 1.53 |
| Interest Coverage | 5.81 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 37.05 | P/B Ratio | 4.36 |
| P/S Ratio | 2.66 | PEG Ratio | -6.70 |
| EV/EBITDA | 19.63 | Dividend Yield | 0.02% |
| Market Cap | 6.63B | Enterprise Value | 8.17B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.49B | 2.29B | 2.14B | 2.07B | 2.04B |
| Net Income | 178.89M | 190.50M | 130.30M | 62.90M | 117.60M |
| EPS (Diluted) | 0.09 | 0.09 | 0.06 | 0.03 | 0.06 |
| Gross Profit | 1.38B | 1.28B | 1.20B | 1.12B | 1.12B |
| Operating Income | 416.05M | 324.90M | 262.70M | 207.30M | 203.60M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3.79B | 3.52B | 3.71B | 3.59B | 3.67B |
| Total Liabilities | 2.27B | 1.83B | 2.02B | 1.98B | 1.98B |
| Shareholders' Equity | 1.52B | 1.69B | 1.69B | 1.61B | 1.69B |
| Total Debt | 1.61B | 1.20B | 1.31B | 1.32B | 1.44B |
| Cash & Equivalents | 75.12M | 64.70M | 97.60M | 143.80M | 463.40M |
| Current Assets | 941.50M | 793.30M | 870.00M | 889.30M | 1.11B |
| Current Liabilities | 616.98M | 512.30M | 536.40M | 533.10M | 569.20M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#652 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026